Company: EDSA
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001171843-25-002028
Chunk: 40

Company: Edesa Biotech, Inc.
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 40
---
 amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our company’s share price at the end and the beginning of the measurement period by our company’s share price at the beginning of the measurement period. No dividends were paid on shares or option awards in 2024, 2023 or 2022.                                                                                                                                                                                                               |
| (5) | The dollar amounts reported represent the amount of net loss reflected in our consolidated audited financial statements for the applicable year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

Analysis of the Information Presented in the Pay Versus Performance

A portion of our NEOs’ compensation consists of equity awards. As a result, the change between the values disclosed in our Summary Compensation Table and Compensation Actually Paid tends to be directionally aligned with changes in our total shareholder return (“TSR”).

While we are required by SEC rules to disclose the relationship between our net income (loss) and Compensation Actually Paid to our NEOs, this is not a metric our compensation committee currently uses in evaluating our NEOs’ compensation as we are a clinical stage biopharmaceutical company that has not generated revenues from the sale of products.

All information provided above under the“Pay Versus Performance”heading will not be deemed to be incorporated by reference in any filing of our company under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

<div align='center'>DIRECTOR COMPENSATION</div>

The following table sets forth information concerning the compensation paid to certain of our non-employee directors during 2024.

| Name                     |     | Fees Earned or Paid in Cash ($) |        |     | Option Awards ($) (1) |   |     | Total ($) |        |
|:-------------------------|:----|:--------------------------------|-------:|:----|:----------------------|:--|:----|:----------|-------:|
| Joan Chypyha             |     | $                               | 51,500 |     | $                     | - |     | $         | 51,500 |
| Sean MacDonald           |     |                                 | 35,000 |     |                       | - |     |           | 35,000 |
| Patrick Marshall         |     |                                 | 47,000 |     |                       | - |     |           | 47,000 |
| Frank Oakes              |     |                                 | 48,500 |     |                       | - |     |